
Linda Wooldridge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5369429/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Young infants exhibit robust functional antibody responses and restrained IFN-Î ³ production to SARS-CoV-2. Cell Reports Medicine, 2021, 2, 100327.	6.5	29
2	Synthetic Peptides with Inadvertent Chemical Modifications Can Activate Potentially Autoreactive T Cells. Journal of Immunology, 2021, 207, 1009-1017.	0.8	3
3	CD8 coreceptor-mediated focusing can reorder the agonist hierarchy of peptide ligands recognized via the T cell receptor. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	6
4	GPU-Accelerated Discovery of Pathogen-Derived Molecular Mimics of a T-Cell Insulin Epitope. Frontiers in Immunology, 2020, 11, 296.	4.8	10
5	Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs. Molecular Therapy, 2018, 26, 1206-1214.	8.2	33
6	Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vl²+ expansions. Scientific Reports, 2018, 8, 2534.	3.3	2
7	Structural Mechanism Underpinning Cross-reactivity of a CD8+ T-cell Clone That Recognizes a Peptide Derived from Human Telomerase Reverse Transcriptase. Journal of Biological Chemistry, 2017, 292, 802-813.	3.4	23
8	CD8 + T ell specificity is compromised at a defined MHCI/CD8 affinity threshold. Immunology and Cell Biology, 2017, 95, 68-76.	2.3	14
9	Lack of Heterologous Cross-reactivity toward HLA-A*02:01 Restricted Viral Epitopes Is Underpinned by Distinct αβT Cell Receptor Signatures. Journal of Biological Chemistry, 2016, 291, 24335-24351.	3.4	23
10	Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies. Scientific Reports, 2016, 6, 35332.	3.3	27
11	Identification of human viral proteinâ€derived ligands recognized by individual MHClâ€restricted Tâ€cell receptors. Immunology and Cell Biology, 2016, 94, 573-582.	2.3	25
12	Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. Journal of Clinical Investigation, 2016, 126, 2191-2204.	8.2	113
13	Clinical research: developing an appropriate career structure. Veterinary Record, 2015, 177, 544-547.	0.3	Ο
14	Naive CD8 ⁺ Tâ€cell precursors display structured TCR repertoires and composite antigenâ€driven selection dynamics. Immunology and Cell Biology, 2015, 93, 625-633.	2.3	48
15	Epitope Specificity Delimits the Functional Capabilities of Vaccine-Induced CD8 T Cell Populations. Journal of Immunology, 2014, 193, 5626-5636.	0.8	7
16	Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood, 2013, 121, 1112-1123.	1.4	89
17	Human β-Cell Killing by Autoreactive Preproinsulin-Specific CD8 T Cells Is Predominantly Granule-Mediated With the Potency Dependent Upon T-Cell Receptor Avidity. Diabetes, 2013, 62, 205-213.	0.6	53
18	Co-Receptor CD8-Mediated Modulation of T-Cell Receptor Functional Sensitivity and Epitope Recognition Degeneracy. Frontiers in Immunology, 2013, 4, 329.	4.8	8

LINDA WOOLDRIDGE

#	Article	IF	CITATIONS
19	Cellular-Level Versus Receptor-Level Response Threshold Hierarchies in T-Cell Activation. Frontiers in Immunology, 2013, 4, 250.	4.8	24
20	Individual MHCI-Restricted T-Cell Receptors are Characterized by a Unique Peptide Recognition Signature. Frontiers in Immunology, 2013, 4, 199.	4.8	8
21	The Nucleocapsid Protein of Rift Valley Fever Virus Is a Potent Human CD8+ T Cell Antigen and Elicits Memory Responses. PLoS ONE, 2013, 8, e59210.	2.5	27
22	A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides. Journal of Biological Chemistry, 2012, 287, 1168-1177.	3.4	374
23	Structural basis for the killing of human beta cells by CD8+ T cells in type 1 diabetes. Nature Immunology, 2012, 13, 283-289.	14.5	151
24	T-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen Targeting*. Journal of Biological Chemistry, 2012, 287, 37269-37281.	3.4	42
25	The molecular determinants of <scp>CD</scp> 8 coâ€receptor function. Immunology, 2012, 137, 139-148.	4.4	51
26	Avidity of influenzaâ€specific memory <scp>CD</scp> 8 ⁺ <scp>T</scp> â€cell populations decays over time compromising antiviral immunity. European Journal of Immunology, 2012, 42, 3235-3242.	2.9	3
27	Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood, 2011, 118, 2138-2149.	1.4	103
28	The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells. Journal of Leukocyte Biology, 2011, 90, 1089-1099.	3.3	20
29	Anti-CD8 Antibodies Can Trigger CD8+ T Cell Effector Function in the Absence of TCR Engagement and Improve Peptide–MHCI Tetramer Staining. Journal of Immunology, 2011, 187, 654-663.	0.8	34
30	MHC Class I Molecules with Superenhanced CD8 Binding Properties Bypass the Requirement for Cognate TCR Recognition and Nonspecifically Activate CTLs. Journal of Immunology, 2010, 184, 3357-3366.	0.8	26
31	CD8 Controls T Cell Cross-Reactivity. Journal of Immunology, 2010, 185, 4625-4632.	0.8	75
32	Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition. Journal of Immunology, 2010, 185, 2600-2610.	0.8	111
33	Ca2+ Release from the Endoplasmic Reticulum of NY-ESO-1–Specific T Cells Is Modulated by the Affinity of TCR and by the Use of the CD8 Coreceptor. Journal of Immunology, 2010, 184, 1829-1839.	0.8	36
34	Genetic and Structural Basis for Selection of a Ubiquitous T Cell Receptor Deployed in Epstein-Barr Virus Infection. PLoS Pathogens, 2010, 6, e1001198.	4.7	110
35	Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. Journal of Immunological Methods, 2009, 340, 11-24.	1.4	134
36	ELISPOT and functional T cell analyses using HLA mono-specific target cells. Journal of Immunological Methods, 2009, 350, 150-160.	1.4	2

#	Article	IF	CITATIONS
37	Tricks with tetramers: how to get the most from multimeric peptide–MHC. Immunology, 2009, 126, 147-164.	4.4	162
38	Techniques to improve the direct ex vivo detection of low frequency antigenâ€specific CD8 ⁺ T cells with peptideâ€major histocompatibility complex class I tetramers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1001-1009.	1.5	49
39	Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. Journal of Immunological Methods, 2008, 338, 31-39.	1.4	32
40	Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib. Clinical Cancer Research, 2008, 14, 2484-2491.	7.0	131
41	Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties. Journal of Biological Chemistry, 2007, 282, 23799-23810.	3.4	198
42	Functional and biophysical characterization of an HLA-A*6801-restricted HIV-specific T cell receptor. European Journal of Immunology, 2007, 37, 479-486.	2.9	21
43	Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. European Journal of Immunology, 2007, 37, 1323-1333.	2.9	60
44	Coreceptor CD8-driven modulation of T cell antigen receptor specificity. Journal of Theoretical Biology, 2007, 249, 395-408.	1.7	35
45	Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. European Journal of Immunology, 2006, 36, 1847-1855.	2.9	22
46	Interaction between the CD8 Coreceptor and Major Histocompatibility Complex Class I Stabilizes T Cell Receptor-Antigen Complexes at the Cell Surface*. Journal of Biological Chemistry, 2005, 280, 27491-27501.	3.4	150
47	Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. Journal of Experimental Medicine, 2005, 202, 1349-1361.	8.5	360
48	Structural and kinetic basis for heightened immunogenicity of T cell vaccines. Journal of Experimental Medicine, 2005, 201, 1243-1255.	8.5	248
49	Anti-CD8 Antibodies Can Inhibit or Enhance Peptide-MHC Class I (pMHCI) Multimer Binding: This Is Paralleled by Their Effects on CTL Activation and Occurs in the Absence of an Interaction between pMHCI and CD8 on the Cell Surface. Journal of Immunology, 2003, 171, 6650-6660.	0.8	51
50	The CD8 T Cell Coreceptor Exhibits Disproportionate Biological Activity at Extremely Low Binding Affinities. Journal of Biological Chemistry, 2003, 278, 24285-24293.	3.4	84
51	High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining. Journal of Immunology, 2003, 171, 5116-5123.	0.8	85